Clinical Trial Update: Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study evaluating GNT0003 after imlifidase pre-treatment in severe Crigler-Najjar syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crigler-najjar Syndrome

Drugs mentioned

• GNT0003
• Imlifidase (imlifidase)

Snippet

Sponsor: Genethon | Conditions: Crigler-Najjar Syndrome | Phase 2 | Status: RECRUITING